Loading
A phase 2 trial of Enzalutamide, Abiraterone acetate, Prednisone in prostate cancer, run by Astellas Pharma Global Development, Inc., active and no longer recruiting.
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study is a phase 2 interventional study registered as NCT02960022 by Astellas Pharma Global Development, Inc., with 900 participants planned, started 2016-12-22 and due to reach its primary completion in 2029-07-31. Interventions recorded: enzalutamide, abiraterone acetate, prednisone, Leuprolide acetate. Conditions listed: Prostate Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Astellas, Abiraterone acetate, Prednisone, Prostate cancer.
Shares Astellas, Enzalutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Abiraterone acetate, Androgen deprivation & AR pathway inhibitors, Prednisone, Prostate cancer.
Shares Abiraterone acetate, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Abiraterone acetate, Enzalutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Abiraterone acetate, Prednisone, Prostate cancer.
Shares Abiraterone acetate, Enzalutamide, Prostate cancer.
Shares Astellas, Enzalutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/